C17 Research Network and 100% Fund Grant Competition — call for LOI [due 14-Dec-2018]

C17 is pleased to announce the call for LOI for the The 100% Fund C17 Grant Competition and Round 22 of the C17 Research Network Operating Grant Competition.

The C17 Operating Grant Competition is focused on multicenter, multidisciplinary pediatric oncology and hematology research.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing the hard-to-treat cancer types below will be considered for the fall 2018 100% Fund Grant Competition.

Please see the calls for LOI, LOI forms and C17 Award Guide documents, linked below.

The submission deadline for C17 LOIs is December 14, 2018 at 4 PM MST.

The application form and guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

Advertisements

Release of COG LTFU Guidelines, Version 5.0

Dear COG Member,

I am pleased to announce the release of Version 5.0 of the Children’s Oncology Group Long-Term Follow-Up Guidelines.  Since 2003, the COG LTFU Guidelines have been integral to directing the long-term follow-up care provided by COG institutions for survivors of childhood, adolescent, and young adults cancers.

There are significant changes to Version 5.0 of these guidelines, including simplification of the design and format, re-definition of the radiation fields, and elimination of most radiation dose cut-offs.  Details of the revisions are summarized in the guideline front-matter (see “New to Version 5.0”).

Over 150 of our members contributed to the current guideline revisions. These efforts were led by the Guideline Core Committee (Melissa Hudson, Wendy Landier, Louis S. Constine, and Smita Bhatia) within the Outcomes and Survivorship Committee under the leadership of Eric Chow, with the generous support of St. Baldrick’s Foundation.

The updated COG LTFU Guidelines Version 5.0, and associated materials for their clinical application, are now available at www.survivorshipguidelines.org.

Sincerely,

Peter C. Adamson MD

Chair, Children’s Oncology Group

N2 fall newsletter includes updates to French CITI courses, info on the N2 SOP tool, and how to access ACRP Ethics and Human Subjects Protection course free of charge

Excerpts from the newsletter are below–read the whole newsletter at https://mailchi.mp/6669b546f52d/read-the-fall-n2-newsletter

Updates to CITI Courses!

The French GCP Refresher course is now available to N2 members. It has been translated into French from the current CITI Canada E6 (R2) compliant GCP Refresher course. Shelley is working with institutional administrators to add the course to N2 member sites. Please allow 5-10 business days for the requests to be processed.

ACRP Ethics and Human Subjects Protection courses available at no charge!

After registering select Pricing Without Contacts Hours at the following link:

www.acrpnet.org/courses/ethics-human-subject-protection/

  • Note: there is currently not the ability to generate a completion certificate, instead participants are instructed to take a screenshot of the transcripts area that indicates they have taken the course
  • Sometime in November, ACRP will launch the Refresher course (about 45 minutes in length) to this topic.
  • If there are any questions, David Burnham can be reached at david.burnham@acrpnet.org

Standard Operating Procedure (SOP)

  • The SOP committee is reviewing V7 N2 SOPs to prepare for V8, scheduled to be distributed in April 2019.
  • This committee is encouraging new members to join. Please contact N2 if you are interested.
  • N2 CAREB/ACCER REB SOP committee will reconvene this Fall, working on V.3 to be released in 2019.

N2’s Featured Tool: Standard Operating Procedures (SOPs)

  • Maintenance of one set of investigative site SOPs (version 7) for all Canadian trial sites (community & academic), accepted by Health Canada
  • All “regular” clinical trials, Natural Health products, Medical Devices, Equipment Calibration, Investigator Initiated Research
  • BiospecimenManagement related SOPs via OICR
  • REB SOPs created with CAREB
How to Use This Tool?  Please log onto your N2 Box account from the login page from n2canada.ca. If you have any trouble accessing your account please contact Shelley King at shelley.king@n2canada.ca. Please contact N2 if you need any further help with using SOPs.

Quality Committee Update

There are three tools the committee are working to complete:

  • Quality Management System policy and procedure
  • Study Risk Assessment Tool is a two-level resource
  • Risk-Based Monitoring Plan

The committee has collaborated with Health Canada to collate and analyze feedback received regarding the final draft of the Part C, Division 5 regulations guidance document GUI-0100.

Education & Training Committee Update

There are two courses that are in the process of being reviewed and finalized:

  • RCR Mega Course which is a combination of Life Sciences, Physical Sciences and Social Humanities- Expected release date: end of 2018)
  • Clinical Research Coordinator Course (CRC) – Expected release: early 2019

French GCP Refresher released early this month. The French GCP Basic course is currently being translated and is expected to be released next year.

JOB POSTING: Provincial Lead, Pediatric Oncology, Saskatchewan [closes 2-Dec-2018]

The Saskatchewan Cancer Agency is seeking internal and external applications for a Provincial Lead, Pediatric Oncology to lead this important service, building on the existing program strengths and leveraging the exciting opportunities for patients and families as the province looks forward to the opening of the Jim Pattison Children’s Hospital.

Preference will be given to applicants who are certified in Pediatrics by the Royal College of Physicians and Surgeons of Canada and additional certification in Pediatric Hematology/Oncology, but equivalent qualifications may be considered.

While pediatric benign hematology is not currently within the scope of our Provincial Pediatric Oncology Program, a program review is currently underway, increased integration of these specialties is expected in the near future, and thus familiarity with this area of practice is considered an asset.

The targeted start date for this position is early 2019.

Successful applicants must be in good standing with their local regulatory bodies, and will need to be eligible for licensure with the College of Physicians and Surgeons of Saskatchewan.  In accordance with Canadian immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada.

The Saskatchewan Cancer Agency offers an attractive compensation and benefits package. Please direct questions to Dr. Monica Behl, VP Medical Services & SMO, at Monica.Behl@saskcancer.ca. Interested applicants are invited to submit their curriculum vitae by December 2, 2018 to:

Carolyn Petersen

carolyn.petersen@saskcancer.ca
Physician Recruitment and Retention Consultant
Saskatchewan Cancer Agency
130-1804 McOrmond Drive
Saskatoon, Saskatchewan, Canada   S7S 0A6
Facsimile: 639-635-3002


The Saskatchewan Cancer Agency operates prevention and early detection programs, conducts innovative research and provides safe, patient and family-centred care at our two comprehensive cancer centres – the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre.

Saskatchewan is a growing and prosperous province. We have excellent education opportunities for young and old and we offer a rich cultural and recreational environment to suit families and independent living. Saskatchewan offers a world of endless possibilities.

JOB POSTING: Pediatric Oncologist for the Saskatoon Cancer Center, PERMANENT [closes 31-Dec-2018

The Provincial Pediatric Oncology Program is seeking applications for a Pediatric Oncologist for the Saskatoon Cancer Center, to be a part of a team of six dedicated colleagues across the province of Saskatchewan.  Successful applicants will report to the Provincial Lead, Pediatric Oncology.  All Oncologists receive an academic appointment in the Division of Oncology, College of Medicine, University of Saskatchewan.  Teaching and research responsibilities are an integral part of program activities.

Preference will be given to applicants who are certified in Pediatrics by the Royal College of Physicians and Surgeons of Canada and additional certification in Pediatric Hematology/Oncology, but equivalent qualifications may be considered.

While pediatric benign hematology is not currently within the scope of our Provincial Pediatric Oncology Program, a program review is currently underway, increased integration of these specialties is expected in the near future, and thus currency of practice in this area is considered an asset.

Successful applicants must be in good standing with their local regulatory bodies, and   meet eligibility for licensure with the College of Physicians and Surgeons of Saskatchewan.  In accordance with Canadian immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada.
A competitive compensation package is offered and will be commensurate with experience. The salary range for this position is $327,209 – $422,266 plus benefits.

Please direct questions to Dr. Chris Mpofu, Director, Provincial Pediatric Oncology Program at Chris.Mpofu@saskcancer.ca.  Interested applicants are invited to submit their curriculum vitae by December 31, 2018 to:

Carolyn Petersen

carolyn.petersen@saskcancer.ca
Physician Recruitment and Retention Consultant
Saskatchewan Cancer Agency
130-1804 McOrmond Drive
Saskatoon, Saskatchewan, Canada   S7S 0A6
Facsimile: 639-635-3002


The Saskatchewan Cancer Agency operates prevention and early detection programs, conducts innovative research and provides safe, patient and family-centred care at our two comprehensive cancer centres – the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre.

Saskatchewan is a growing and prosperous province. We have excellent education opportunities for young and old and we offer a rich cultural and recreational environment to suit families and independent living. Saskatchewan offers a world of endless possibilities.

JOB POSTING: Pediatric Oncologist for the Saskatoon Cancer Center, LOCUM [closes 31-Dec-2018

The Provincial Pediatric Oncology Program is seeking applications for a Pediatric Oncologist for the Saskatoon Cancer Center, to be a part of a team of six dedicated colleagues across the province of Saskatchewan.  Successful applicants will report to the Provincial Lead, Pediatric Oncology.  All Oncologists receive an academic appointment in the Division of Oncology, College of Medicine, University of Saskatchewan.  Teaching and research responsibilities are an integral part of program activities.

Preference will be given to applicants who are certified in Pediatrics by the Royal College of Physicians and Surgeons of Canada and additional certification in Pediatric Hematology/Oncology, but equivalent qualifications may be considered.

While pediatric benign hematology is not currently within the scope of our Provincial Pediatric Oncology Program, a program review is currently underway, increased integration of these specialties is expected in the near future, and thus currency of practice in this area is considered an asset.

Successful applicants must be in good standing with their local regulatory bodies, and   meet eligibility for licensure with the College of Physicians and Surgeons of Saskatchewan.  In accordance with Canadian immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada.
A competitive compensation package is offered and will be commensurate with experience. The salary range for this position is $327,209 – $422,266 plus benefits.

Please direct questions to Dr. Chris Mpofu, Director, Provincial Pediatric Oncology Program at Chris.Mpofu@saskcancer.ca.  Interested applicants are invited to submit their curriculum vitae by December 31, 2018 to:

Carolyn Petersen

carolyn.petersen@saskcancer.ca
Physician Recruitment and Retention Consultant
Saskatchewan Cancer Agency
130-1804 McOrmond Drive
Saskatoon, Saskatchewan, Canada   S7S 0A6
Facsimile: 639-635-3002


The Saskatchewan Cancer Agency operates prevention and early detection programs, conducts innovative research and provides safe, patient and family-centred care at our two comprehensive cancer centres – the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre.

Saskatchewan is a growing and prosperous province. We have excellent education opportunities for young and old and we offer a rich cultural and recreational environment to suit families and independent living. Saskatchewan offers a world of endless possibilities.

CADTH Invites Patient Advocacy Group and Registered Clinician Input on: Axicabtagene Ciloleucel (TBD) for Diffuse large B-cell lymphoma (DLBCL)[Due 23-Nov-2018]

This is to notify stakeholders that CADTH is anticipating that a submission will be made for Axicabtagene Ciloleucel (TBD) for diffuse large B-cell lymphoma (DLBCL).

Patient groups that have registered with CADTH are invited to provide input by using the Patient Input Template for CADTH CAR T-Cell Therapy Reviews.

Clinicians and clinician groups that have registered with CADTH are invited to provide input using the Clinician Input Template for Axicabtagene Ciloleucel for Diffuse large B-cell lymphoma (DLBCL).

The targeted deadline for receiving stakeholder input on Axicabtagene Ciloleucel (TBD) for diffuse large B-cell lymphoma (DLBCL) is November 23, 2018 by 5:00 p.m. Eastern Time. This submission is now open for input and patient group and clinician submissions can be made through the CADTH website.

Patient groups and clinicians who have not yet registered with CADTH and would like to provide input are invited to visit CADTH Registration for details on registration.


About CADTH

CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Learn more at: www.cadth.ca.

JOB POSTING: Part-Time Clinical Research Associate for CYP-C data entry, Hem/Onc/BMT at BC Children’s Hospital

UBC Department of Pediatrics and the Division of Hem/Onc/BMT at BC Children’s Hospital is looking for a Part-Time Clinical Research Associate (Tech 3) to coordinate data collection and management for the national pediatric oncology surveillance program (CYP-C: Cancer in Young People in Canada). Knowledge of medical terminology, experience with complex data abstraction and ability to work quickly and accurately is preferred. Job ID: 31719.

The job posting is available here: https://www.hr.ubc.ca/jobs/staff.php?job_id=31719

It will be posted for applications through the end of Nov 4, 2018 . Only shortlisted candidates will be contacted.

Sign up for the free informational webinar hosted by CARA about clinical research tools and resources to support your work from N2!

CARA is hosting a free webinar for both CARA and N2 members about clinical research tools and resources that are available to support your work and available through your N2 membership. Details are below. After registering, you will receive a confirmation email containing information about joining the webinar

Date and Time: Friday, November 2, 2018
Time: 12:00 PM EST
Cost: Free!

Register at: https://zoom.us/webinar/register/WN_l2IktXiWTUqfVwDWMoqL0g

Aidez à actualiser la stratégie sur le cancer du Canada

Comme vous le savez, le Canada est confronté à des défis actuels et nouveaux en matière de lutte contre le cancer, notamment le vieillissement de la population, qui impose des exigences accrues sur les services de soins, l’augmentation des coûts des soins de santé et les inégalités touchant les populations mal desservies et sous-représentées. La ministre fédérale de la Santé a demandé au Partenariat canadien contre le cancer d’actualiser la Stratégie canadienne de lutte contre le cancer. Celle-ci doit évoluer pour nous aider à répondre à ces besoins changeants et permettre au Canada de demeurer un chef de file en matière de prestation de soins liés au cancer de grande qualité.

Comment pouvez-vous participer?

Visitez le site strategiesurlecancer.ca pour présenter une soumission préparée par votre organisation en réponse au document de travail et pour participer à titre personnel au sondage Livre de choixMC.

Adressez-vous à notre équipe pour leur faire part de vos histoires, de vos expériences et de vos priorités en tant que membre des Premières Nations, des Inuits et des Métis.

 Partagez ce message avec vos collègues, votre famille et vos amis, et encouragez-les à participer.

Votre opinion et votre expertise sont essentielles à l’avancement de la Stratégie canadienne de lutte contre le cancer, et nous vous remercions de votre intérêt et de votre participation. En mai 2019, nous ferons part à la ministre de la Santé des points de vue exprimés partout au pays. Pour toute question supplémentaire, veuillez envoyer un courriel à info@cancerstrategy.ca.

Meilleures salutations,

Cindy Morton, PDG
Partenariat canadien contre le cancer

 

Restez en contact

Vous souhaitez être tenu au courant des progrès de l’actualisation de la Stratégie canadienne de lutte contre le cancer? Inscrivez-vous pour recevoir les dernières nouvelles.